COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer
Por:
Herbst R, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge D, Winzer L, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A
Publicada:
10 oct 2022
Resumen:
|